Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

BACKGROUND: Alectinib, a highly selective, central nervous system (CNS)-active anaplastic lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve and crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC). This phase 2 study evaluated the safety an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Autores principales: Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ignatius Ou, Sai-Hong
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
https://ncbi.nlm.nih.gov/pubmed/26708155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00488-X
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares